ArticleVirology journal2026
Acute hepatitis E in older adults: global trends from the global burden of disease study.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extra-Hepatic Manifestations of Hepatitis E Virus (HEV): A Narrative Review on Meningoencephalitis.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsHepatitis E virus (HEV) infection poses an increasing threat to the health of older adults, yet global epidemiological data on this susceptible population remain limited. This study aims to evaluate long-term trends in the incidence and mortality of acute hepatitis E (AHE) among individuals aged 60 years and older, with a focus on demographic, regional, and socioeconomic disparities.
methodsIn this study, we used GBD data from 2021 to assess the incidence and mortality rates associated with the HEV in older populations. We quantified incidence rates, determined average annual percentage changes, and analysed global trends across age, sex, and socio-demographic index (SDI) levels. Health inequality was evaluated via the Slope Index of Inequality (SII) and Concentration Index (CI). Additionally, we employed the Bayesian Age-Period-Cohort model to project the incidence of and mortality from HEV among older adults by 2030.
resultsFrom 1990 to 2021, the global age-standardized incidence of AHE among older adults remained stable, while mortality declined (AAPC: − 2.9%). Notably, incidence increased substantially within the oldest age groups, particularly among those aged 75–94 years, and was consistently higher in females than in males across all age groups. Mortality decreased across most age groups, with the most pronounced reductions in individuals under 80. Substantial regional and socioeconomic disparities persisted, with low-SDI countries bearing a heavier burden. By 2030, incidence is expected to rise with age, while male mortality will remain markedly higher than that of females.
conclusionsThe burden of AHE among older adults remains substantial and unequally distributed. As the global population ages, targeted interventions are urgently needed to reduce disease burden and health disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.